Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
doi: https://doi.org/10.1101/2021.05.03.21256309

Article Information

doi 
https://doi.org/10.1101/2021.05.03.21256309
History 
  • May 5, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Saye H Khoo†,*,1,2,
  2. Richard FitzGerald†,2,
  3. Thomas Fletcher2,3,
  4. Sean Ewings4,
  5. Thomas Jaki5,6,
  6. Rebecca Lyon2,
  7. Nichola Downs4,
  8. Lauren Walker2,
  9. Olana Tansley-Hancock4,
  10. William Greenhalf1,
  11. Christie Woods2,
  12. Helen Reynolds1,
  13. Ellice Marwood4,
  14. Pavel Mozgunov5,
  15. Emily Adams3,
  16. Katie Bullock1,
  17. Wayne Holman7,
  18. Marcin D Bula4,
  19. Jennifer L Gibney2,
  20. Geoffrey Saunders4,
  21. Andrea Corkhill4,
  22. Colin Hale2,
  23. Kerensa Thorne4,
  24. Justin Chiong1,
  25. Susannah Condie4,
  26. Henry Pertinez1,
  27. Wendy Painter7,
  28. Emma Wrixon4,
  29. Lucy Johnson4,
  30. Sara Yeats4,
  31. Kim Mallard4,
  32. Mike Radford4,
  33. Keira Fines4,
  34. Victoria Shaw1,
  35. Andrew Owen1,
  36. David G Lalloo3,
  37. Michael Jacobs8 and
  38. Gareth Griffiths4
  1. 1University of Liverpool, UK
  2. 2Liverpool University Hospital NHS Foundation Trust, UK
  3. 3Liverpool School of Tropical Medicine, UK
  4. 4Southampton Clinical Trials Unit, UK
  5. 5University of Lancaster, UK
  6. 6MRC Biostatistics Unit, University of Cambridge, UK
  7. 7Ridgeback Biotherapeutics, Miami, USA
  8. 8Royal Free London NHS Foundation Trust, UK
  1. ↵*Corresponding Author: Professor S.H. Khoo, khoo{at}liverpool.ac.uk, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, UK, T +44151 794 5560, F +44151 794 5656

  1. ↵† Contributed equally

Back to top
Posted May 05, 2021.
Download PDF
Data/Code
Email
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
Saye H Khoo, Richard FitzGerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Rebecca Lyon, Nichola Downs, Lauren Walker, Olana Tansley-Hancock, William Greenhalf, Christie Woods, Helen Reynolds, Ellice Marwood, Pavel Mozgunov, Emily Adams, Katie Bullock, Wayne Holman, Marcin D Bula, Jennifer L Gibney, Geoffrey Saunders, Andrea Corkhill, Colin Hale, Kerensa Thorne, Justin Chiong, Susannah Condie, Henry Pertinez, Wendy Painter, Emma Wrixon, Lucy Johnson, Sara Yeats, Kim Mallard, Mike Radford, Keira Fines, Victoria Shaw, Andrew Owen, David G Lalloo, Michael Jacobs, Gareth Griffiths
medRxiv 2021.05.03.21256309; doi: https://doi.org/10.1101/2021.05.03.21256309
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area